share_log

Earnings Are Growing at 3SBio (HKG:1530) but Shareholders Still Don't Like Its Prospects

Earnings Are Growing at 3SBio (HKG:1530) but Shareholders Still Don't Like Its Prospects

3sBio(HKG: 1530)的收益正在增長,但股東們仍然不喜歡它的前景
Simply Wall St ·  2023/11/13 17:23

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the main game is to find enough winners to more than offset the losers At this point some shareholders may be questioning their investment in 3SBio Inc. (HKG:1530), since the last five years saw the share price fall 45%. On top of that, the share price is down 8.3% in the last week.

爲了證明選擇個股的努力是合理的,值得努力超過市場指數基金的回報。但主要的遊戲是找到足夠的贏家來抵消輸家。此時,一些股東可能會質疑他們對3sBio Inc.(HKG: 1530)的投資,因爲過去五年股價下跌了45%。最重要的是,上週股價下跌了8.3%。

Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.

鑑於過去一週對股東的處境艱難,讓我們研究一下基本面,看看能學到什麼。

Check out our latest analysis for 3SBio

查看我們對 3sBio 的最新分析

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

在他的文章中 格雷厄姆和多茲維爾的超級投資者 沃倫·巴菲特描述了股價如何並不總是能合理地反映企業的價值。通過比較每股收益(EPS)和股價隨時間推移的變化,我們可以了解投資者對公司的態度如何隨着時間的推移而變化。

During the unfortunate half decade during which the share price slipped, 3SBio actually saw its earnings per share (EPS) improve by 14% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Alternatively, growth expectations may have been unreasonable in the past.

在股價下滑的不幸的五年中,3sBio的每股收益(EPS)實際上每年增長14%。鑑於股價的反應,人們可能會懷疑每股收益並不能很好地指導該期間的業務表現(可能是由於一次性的虧損或收益)。或者,過去的增長預期可能不合理。

Because of the sharp contrast between the EPS growth rate and the share price growth, we're inclined to look to other metrics to understand the changing market sentiment around the stock.

由於每股收益增長率與股價增長形成鮮明對比,我們傾向於研究其他指標來了解圍繞該股不斷變化的市場情緒。

We don't think that the 1.4% is big factor in the share price, since it's quite small, as dividends go. In contrast to the share price, revenue has actually increased by 10% a year in the five year period. A more detailed examination of the revenue and earnings may or may not explain why the share price languishes; there could be an opportunity.

我們認爲1.4%不是影響股價的重要因素,因爲隨着股息的增加,它相當小。與股價形成鮮明對比的是,在五年期間,收入實際上每年增長10%。對收入和收益進行更詳細的審查可能會也可能無法解釋股價下跌的原因;可能有機會。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下圖描繪了收入和收入隨着時間的推移而發生的變化(點擊圖片顯示確切的數值)。

earnings-and-revenue-growth
SEHK:1530 Earnings and Revenue Growth November 13th 2023
SEHK: 1530 2023年11月13日收益和收入增長

We know that 3SBio has improved its bottom line lately, but what does the future have in store? So we recommend checking out this free report showing consensus forecasts

我們知道3sBio最近提高了利潤,但是未來會發生什麼?因此,我們建議您查看這份顯示共識預測的免費報告

What About Dividends?

那股息呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, 3SBio's TSR for the last 5 years was -42%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

在考慮投資回報時,重要的是要考慮兩者之間的區別 股東總回報率 (TSR) 和 股價回報。股東總回報率是一種回報計算方法,它考慮了現金分紅的價值(假設收到的任何股息都經過再投資)以及任何貼現資本籌集和分拆的計算價值。可以公平地說,股東總回報率爲支付股息的股票提供了更完整的畫面。碰巧的是,3sBio過去5年的股東總回報率爲-42%,超過了前面提到的股價回報率。這在很大程度上是其股息支付的結果!

A Different Perspective

不同的視角

While the broader market gained around 3.2% in the last year, 3SBio shareholders lost 6.8% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. However, the loss over the last year isn't as bad as the 7% per annum loss investors have suffered over the last half decade. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. Before deciding if you like the current share price, check how 3SBio scores on these 3 valuation metrics.

儘管去年整體市場上漲了約3.2%,但3sBio的股東損失了6.8%(甚至包括股息)。即使是優質股票的股價有時也會下跌,但我們希望在過於感興趣之前看到企業基本指標的改善。但是,去年的虧損沒有投資者在過去五年中遭受的每年7%的損失那麼嚴重。在認爲股價將穩定之前,我們希望獲得明確的信息,表明該公司將增長。在決定是否喜歡當前股價之前,請查看3sBio在這三個估值指標上的得分情況。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你想和管理層一起購買股票,那麼你可能會喜歡這份免費的公司清單。(提示:內部人士一直在買入它們)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.

請注意,本文引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報率。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論